p27在卵巢癌中的表达及其与细胞增殖活性的相关性研究

目的:旨在研究卵巢癌中p27的表达及其与细胞增殖活性的关系,为进一步探讨p27在卵巢癌发生、发展中的生物学意义及卵巢癌的基因治疗提供实验依据。方法:应用增殖细胞核抗原(proliferatingcellnuclearantigen,PCNA)标记指数作为肿瘤细胞增殖活性的参数,采用S-P法对42例卵巢癌,21例卵巢上皮肿瘤,10例正常卵巢组织标本进行免疫组化染色。检测所有标本中p27的表达,分析其与良恶性肿瘤、病理学分级及细胞增殖活性的关系。结果:p27阳性率和平均标记指数(meanlabellingindices,MLI)在卵巢癌中的表达明显低于正常卵巢上皮组织和卵巢良性肿瘤(P<0.01)。此外,随着卵巢癌病理分级的增高,p27的阳性率和平均标记指数呈降低趋势,在各级卵巢癌之间有显著性差异(P<0.01)。研究表明,p27标记指数与PCNA标记指数呈负相关(r=-0.632,P<0.01)。结论:p27在卵巢癌中呈低表达或表达缺失,可能与卵巢癌的发生发展密切相关。p27在卵巢癌中的表达与肿瘤的恶性程度、细胞的增殖活性密切相关。为进一步探讨p27在卵巢癌发生、发展中的生物学意义及卵巢癌的基因治疗提供实验依据。     

玻璃体切除联合白内障摘出人工晶状体植入术

目的探讨玻璃体切除联合白内障摘出及人工晶状体植入术的临床效果。方法对16例(17眼)玻璃体视网膜疾病伴有明显的白内障者实施了此联合手术。先行常规白内障囊外摘出术或晶状体超声乳化术,再行标准三通道闭合式玻璃体切除术,最后植入人工晶状体。结果术后随访2月～3年,平均13月。16眼术后视力均有不同程度提高,1眼增生性糖尿病性视网膜病变术后2月因继发新生血管性青光眼,行广泛视网膜冷凝后视力下降。术后早期16例(17眼)均有不同程度的角膜后弹力层皱褶,术后7～10d消失。2例(2眼)术后有一过性眼压升高。1例(1眼)术后2月发生新生血管性青光眼。3例(3眼)术后后囊浑浊,未影响视力。结论此联合手术的临床效果良好,具有一定的优点,但应严格掌握适应证,并要求有熟练的手术技巧。     

6个中药单体对结肠腺癌细胞SW620体外增殖活性的影响

目的考察并比较苦参中苦参碱、氧化苦参碱,大黄中大黄素、芦荟大黄素,三七中的人参皂苷Rh2、Rgl等6个成分对结肠腺癌细胞株SW620体外增殖活性的影响。方法采用MTT法检测不同浓度各成分分别作用24h、48h对体外培养的结肠腺癌细胞SW620增殖抑制率,并每天于显微镜下观察细胞生长情况。结果与对照组比较,各成分在一定剂量范围内均能不同程度地抑制细胞增殖,其作用呈剂量和时间依赖性。结论各成分均能抑制体外培养的细胞增殖,尤以芦荟大黄素的活性最强。     

增生性糖尿病视网膜病变的生物信息与不同海拔患者相关性研究

【摘要】目的 通过对RNA Seq高通量测序数据进行生物信息学分析,同时结合青海省不同海拔地区患者的发病情况,探讨增生性糖尿病视网膜病变的发病机制,为该病的早期诊断提供新的思路。方法 从NCBI的GEO公共数据库中下载与增生性糖尿病视网膜病变相关的RNA Seq高通量测序数据,利用R语言对差异基因进行筛选,通过DAVID在线工具对差异基因进行GO富集及信号通路分析,利用STRING对差异基因进行蛋白相互作用网络分析。利用实时荧光定量PCR技术分析ACSL5、IGF和CPS1基因在不同海拔患者中的mRNA表达情况,最后,借助于Protein isoelectric point calculator、SignalP 41 Server、Kyte Doolittle Hydropathy Plots、TMHMM Server、ExPasy、RasMol等工具对IGF基因及蛋白质进行理化性质分析及三维结构功能分析。结果 共筛选出97个差异基因,其中60个基因表达上调,37个基因表达下调,这些差异基因参与多种生物学过程及信号通路,通过STRING蛋白网络互作分析,共筛选出10个潜在的与增生性糖尿病视网膜病变相关的节点基因。结论 10个基因可能是该病潜在的治疗靶点,而又以ACSL5、CPS1和IGF三种基因尤为重要,与增生性糖尿病视网膜病变的发病情况密切相关;提示ACSL5、CPS1和IGF可成为高原不同海拔地区增生性糖尿病视网膜病变的早期诊断指标。     

增殖性玻璃体视网膜病变发病机制及研究进展

增殖性玻璃体视网膜病变主要是孔源性视网膜脱离后长时间未得到复位,在玻璃体腔及视网膜内外表面未有纤维细胞性膜(无血管)形成和收缩的病变类型;增殖性玻璃体视网膜病变是导致孔源性视网膜脱离复位手术的失败主要原因,与此同时,增殖性玻璃体视网膜病变也是导致视网膜脱离的重要因素,其成因与玻璃体病理性纤维化相关。当前主要采取的治疗手段为手术治疗,但效果并不十分理想。为了进一步提高治疗效果,本文主要就增殖性玻璃体视网膜病变发病机制及研究现状进行相关探讨,以期为增殖性玻璃体视网膜病变的临床治疗提供更为可靠的理论依据。     

Antioxidant and Proliferative Activities of Bupleuri Radix Extract Against Serum Deprivation in SH-SY5Y Cells

Objective

Bupleuri Radix (BR) is a major component of several Oriental herbal medicines used to treat stress and mental illness. There are evidences that antidepressant drugs modulate oxidative damage implicated in the pathophysiology of neuropsychiatric disorder, including depression. The aim of the present study was to investigate antioxidant and proliferative effects of BR against oxidative stress induced by serum deprivation in SH-SY5Y cells.

Methods

We examined the antioxidant effects of BR on a number of measures, including cell viability, formation of reactive oxygen species (ROS), superoxide dismutase (SOD) activity and levels of both Bcl-2 and Bax. We also investigated the effects of BR on cell proliferation using the bromodeoxyuridine (BrdU) assay, and used Western blot analysis to measure changes in expression of the cell cycle phase regulators.

Results

1) Serum deprivation significantly induced the loss of cell viability, the formation of ROS, the reduction of SOD activity, down-regulation of Bcl-2 expression and up-regulation of Bax expression. However, BR extract reversed these effects in dose-dependent manner. 2) Serum deprivation significantly reduced cell proliferation. Western blot analysis revealed that serum deprivation significantly decreased cyclinD1 and phosphorylated retinoblastoma (pRb) expression, and increased p27 expression. On the other hand, BR dose dependently reversed these effects.

Conclusion

This study suggests that aqueous extract of BR may exert potent antioxidant effects and also play an important role in regulating cell cycle progression during neurogenesis. These effects of BR may be a potentially important mechanism of antidepressant underlying the observed antioxidant and proliferative effects.     

Deletions Overlapping VCAN Exon 8 Are New Molecular Defects for Wagner Disease

Wagner disease is a rare nonsyndromic autosomal‐dominant vitreoretinopathy, associated with splice mutations specifically targeting VCAN exon 8. We report the extensive genetic analysis of two Wagner probands, previously found negative for disease‐associated splice mutations. Next‐generation sequencing (NGS), quantitative real‐time PCR, and long‐range PCR identified two deletions (3.4 and 10.5 kb) removing at least one exon–intron boundary of exon 8, and both correlating with an imbalance of VCAN mRNA isoforms. We showed that the 10.5‐kb deletion occurred de novo, causing somatic mosaicism in the proband's mother who had an unusually mild asymmetrical phenotype. Therefore, exon 8 deletions are novel VCAN genetic defects responsible for Wagner disease, and VCAN mosaic mutations may be involved in the pathogenesis of Wagner disease with attenuated phenotype. NGS is then an effective screening tool for genetic diagnosis of Wagner disease, improving the chance of identifying all disease‐causative variants as well as mosaic mutations in VCAN.     

Age-related eye disease

As with many organs, compromised function of the eye is accompanied with age and has become increasingly prevalent with the aging population. When decreased visual loss becomes significant, patients’ ability to perform activities of daily living becomes compromised. This decrease in function is met with morbidity and mortality, as well as a large socioeconomic burdon throughout the world. This review summarizes the most common age-related eye diseases, including cataract, glaucoma, diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration. Although our understanding of the genetic and biochemical pathways of these diseases is sill at its primitive stages, we have become able to help our patients improve the quality of life as they age.     

口服普萘洛尔治疗婴幼儿增生期血管瘤35例临床分析

目的:探讨口服普萘洛尔治疗婴幼儿增生期血管瘤的临床疗效。方法:2009年10月—2011年2月,35例增生期血管瘤患儿在中国医科大学附属口腔医院完成普萘洛尔治疗,按1.0～1.5mg/kg,每天1次口服用药,连续服用,随访1～10个月。收集每例患儿的相关资料,包括临床特征、疗效和不良反应。采用半球测量法和数码照片记录患儿血管瘤大小,按家长反馈信息和4级评分法对疗效进行评价。结果:口服普萘洛尔治疗后,大部分血管瘤体积明显减小,颜色变淡,质地变软,家长满意度好,不良反应轻微。疗效评定为Ⅳ级(优)者6例,Ⅲ级(好)16例,Ⅱ级(中)10例,I级(差)3例。结论:口服普萘洛尔作为一种新型的治疗方式,用药安全,疗效明显,对体积较大的血管瘤疗效显著。